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cohorts, and robust data for long-term treatment effects are lacking.Methods According to uniform inclusion criteria, 275 recently diagnosed consecutive pediatric PAH patients who visited
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2160States, including 1 study of a
cohort of children followed in 2
major US referral centers and 1
of a subgroup of patients with
childhood-onset PAH included
in a U.S.-based multicenter PAH
registry (REVEAL [Registry to
Evaluate Early and Long-Term
PAH Disease Management])
(6–10). In all cohorts, the reported
survival seemed to be improved
compared to historical reports.
However, intriguingly, the re-
ported survival rates appeared
to differ signiﬁcantly between the
European and U.S. reports.
No direct comparisons can
be made between these reported
survival rates due to differences in
inclusion criteria, patient char-
acteristics, and data collection.
Nevertheless, these discrepancies
in survival are of interest, because
they might be a consequence
of varying patient characteristics
or different treatment strategies
adopted by the reporting centers.
Therefore, they may reveal infor-
mation on the importance of
clinical predictors of survival and
on the optimal treatment strategy.We directly compared patient characteristics, treatment
strategies, and outcomes and identiﬁed predictors of out-
come in pediatric PAH patients seen on both sides of the
Atlantic Ocean, speciﬁcally those seen in 2 major referral
centers in the United States (New York, New York, and
Denver, Colorado) and those seen in a national referral
center for pediatric PAH based in Europe (the Netherlands)
using similar standardized inclusion criteria.
Methods
Patient data were retrospectively collected from 3 major
referral centers for pediatric PAH: 2 U.S.-based centers, the
Children’s Hospital Colorado, Denver, Colorado (Denver
cohort) and Columbia University Medical Center, New
York, New York (NY cohort) and 1 Europe-based center,
the University Medical Center Groningen/Beatrix Children’s
Hospital, Groningen (Dutch cohort). The Europe-based
center serves as the national referral center for pulmonary
hypertension (PH) in childhood in the Netherlands. All
Dutch children with (suspected) PAH are referred to this
center for diagnostic workup, treatment, and follow-up. It
therefore follows a national cohort of children with PAH.
Patients. To deﬁne patient cohorts in a way that allowed
for direct comparison, we used uniform inclusion criteria: allpediatric PAH (group 1 PH, Dana Point classiﬁcation [11])
patients who visited the 3 referral centers between 2000
through 2010, diagnosed by cardiac catheterization at <18
years of age, were included. Diagnosis of PAH was deﬁned
as mean pulmonary arterial pressure 25 mm Hg, mean
pulmonary capillary wedge pressure 15 mm Hg, and
pulmonary vascular resistance index (PVRi) 3 Woods
units$m2. To ensure similar PAH-targeted drug availability
for all studied patients, only patients who visited the referral
centers between 2000 and 2010 were included. To study a
contemporary cohort, only patients diagnosed after 1997
were included. In patients with a corrected heart defect,
diagnosis of PAH was conﬁrmed at least 1 year after
corrective surgery (12). Patients who had pulmonary arterial
pressures normalized while therapy was discontinued were
considered not to have PAH because of the progressive
character of the disease, and were not included. To avoid
double inclusion, 1 patient who switched from one to the
other U.S. center was included in the cohort of the latter
center. All patient data were uniformly collected in a data-
base speciﬁcally designed for this study.
Patients with PH secondary to left heart disease, lung
disease, thromboembolic disease, or PH with unclear
multifactorial mechanisms (group 2 to 5 PH, Dana Point
classiﬁcation [11]) were not included in this study.
Study assessments. Patients were diagnosed according to
the Clinical Classiﬁcation of Pulmonary Hypertension
(Dana Point update) (11). For this study, diagnosis was
classiﬁed as idiopathic or hereditary PAH (IPAH/HPAH),
PAH associated with congenital heart disease (PAH-CHD),
or associated PAH-non-CHD (APAH-non-CHD) (12). In
case of CHD, type of shunt was deﬁned as pre-tricuspid (e.g.,
atrial septal defect), post-tricuspid (e.g., ventricular septal
defect), repaired pre- or repaired post-tricuspid shunt, or as
no previous shunt (e.g., coarctation of the aorta). Further-
more, Eisenmenger syndrome was deﬁned as the presence of
a post-tricuspid shunt with right-to-left shunting and sys-
temic arterial, or if not available, transcutaneous, oxygen
saturation of less than 90%.
Baseline parameters included clinical and hemodynamic
characteristics at diagnosis. Age-normalized scores (z-scores)
for height and body mass index were calculated using World
Health Organization (WHO) child growth standards
(13,14). Mean pulmonary-to-systemic arterial pressure ratios
(mPAP/mSAP), pulmonary-to-systemic vascular resistance
ratios and pulmonary-to-systemic blood ﬂow ratios were
calculated. Acute responder status was determined according
to criteria deﬁned by the REVEAL study for childhood-
onset PAH (10), Barst et al. (15), and Sitbon et al. (16).
Speciﬁc PAH therapy was classiﬁed as either calcium
channel blocker (CCB) therapy without the need for addi-
tional PAH-targeted therapy (CCB monotherapy) or as
PAH-targeted therapy, including prostanoids, endothelin
receptor antagonists, and type 5-phosphodiesterase in-
hibitors. PAH-targeted therapy was further classiﬁed as
monotherapy or as combination therapy with a combination
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administered for at least 3 months or until end of follow-up.
Real-time therapy was cumulatively plotted per center
cohort for visual comparison. Furthermore, treatment
strategy was deﬁned as either CCB monotherapy when a
CCB was the only speciﬁc PAH drug used during the pa-
tient’s disease course or the maximum number of simulta-
neously used PAH-targeted drugs (mono-, dual, or triple
therapy). Also, it was determined whether therapy included
an intravenously (IV) or subcutaneously (SC) administered
prostanoid. Two Dutch patients and 1 Denver patient were
excluded from this latter comparison because their death
within 7 days after diagnosis did not allow for start of spe-
ciﬁc PAH therapy.
Statistical analysis. Data are presented as mean  SD,
median (interquartile range), and number (percentage) of
patients, as appropriate. Patient characteristics, baseline
parameters, and treatment strategy were compared between
the 3 center cohorts, using one-way analysis of variance
(ANOVA) for continuous normally distributed variables,
and Kruskal-Wallis test and Mann Whitney U test for
ordinal and not normally distributed continuous variables.
Multiple chi-square tests and Fisher exact tests were used for
categorical variables. Post-hoc Bonferroni was used to cor-
rect for multiple comparisons, as appropriate.
Survival analyses were based on transplantation-free sur-
vival. Patients who did not die or undergo (heart-)lung
transplantation were censored at the last recorded visit. For
this study, patients who had had their last recorded visit
more than 2 years before the end of the study period were
considered lost to follow-up.
Survival rates were compared between the 3 center cohorts
by using Kaplan-Meier curves with log rank testing. Kaplan-
Meier curves were also used to illustrate the survival of the
patient groups who underwent different treatment strategies.
To determine predictors of survival in the total cohort,
univariate Cox regression analysis was performed. Multi-
variate backward stepwise Cox regression analysis was used
to identify the strongest independent predictors of survival.
P values <0.05 were considered signiﬁcant.
To assess potential overﬁtting, we conducted secondary
sensitivity analyses using bootstrap model selection to assess
independent predictors of survival. This method has been
used previously in the context of a population of coronary
stent thromboses to avoid an overﬁt model (17). Among the
variables, bootstrap selection with 500 models was per-
formed in the full dataset only without natriuretic peptides
due to the substantial number of missing cases, the full
dataset without natriuretic peptides, and blood pressure and,
ﬁnally, the full dataset without natriuretic peptides, blood
pressure, and center (see Table 3).
Results
In total, 275 pediatric patients were included in this study:
135 patients from NY, 93 patients from Denver, and47 patients from the Netherlands. Patient characteristics and
clinical and hemodynamic parameters at time of diagnosis
are shown in Table 1.
Patients were comparable regarding age at diagnosis and
sex. Time between ﬁrst symptoms and diagnosis was
signiﬁcantly longer in the NY cohort than in the Dutch and
Denver cohorts (p < 0.001). In all 3 cohorts, most patients
had diagnoses of IPAH/HPAH or PAH-CHD, although
its distribution differed between the center cohorts. In the
Dutch and NY cohorts, most patients had diagnoses of
IPAH/HPAH versus PAH-CHD in the Denver cohort.
The occurrence of APAH-non-CHD (including PAH
associated with connective tissue disease, human immuno-
deﬁciency virus antibodies, hemolytic anemia, portal hyper-
tension, drugs/toxins, pulmonary capillary hemangiomatosis,
or pulmonary veno-occlusive disease) was higher in the
Dutch cohort than in the NY cohort (p ¼ 0.025).
At time of diagnosis, patients in the Dutch cohort had
higher WHO functional class, shorter 6-min walk distance,
higher PVRi and pulmonary-to-systemic vascular resistance
ratio, and lower systemic blood ﬂow index and mean sys-
temic arterial pressure than the NY and Denver cohorts.
Prevalence of acute responders depended on the criteria
used, ranging from 14% to 19% of the NY patients, 15% to
31% of the Denver patients, and 8% to 25% of the Dutch
patients, and did not differ between the center cohorts.
Treatment. The 7-year cumulative treatment follow-up of
the 3 center cohorts is plotted in Figure 1. The ﬁgure shows
that in all 3 center cohorts, there was a similar, stable per-
centage of patients receiving CCB monotherapy. Consid-
ering PAH-targeted therapy, in all 3 cohorts, most patients
started on monotherapy, with high percentages of patients
on monotherapy within the ﬁrst 3 years after diagnosis.
In time, patients were switched from monotherapy to dual
or triple therapy. In all 3 center cohorts a small number
of patients received no speciﬁc PAH therapy within this
7-year period. These patients either died shortly after
diagnosis before therapy could be started, received therapy
after 7 years of follow-up, or received no therapy because
their low WHO functional classiﬁcation at that time did
not warrant therapy according to evolving treatment stra-
tegies. Furthermore, the ﬁgure illustrates a higher mortality
rate in the Dutch cohort and a higher percentage of patients
lost to follow-up in the Denver and NY cohorts. The dis-
tribution of treatment strategy did not differ among the
center cohorts (Table 2).
Transplantation-free survival and predictors of prognosis.
Follow-up time ranged from 0.01 to 13.7 years (median, 4.0
years). During the study period, 7 NY patients (5%), 18
Denver patients (19%), and 15 Dutch patients (32%) died.
Furthermore, 6 NY patients (4%) and 1 Dutch patient (2%)
underwent lung transplantation. Overall, 1-, 3-, 5-, and
7-year transplantation-free survival rates were 96%, 89%,
81%, and 79%, respectively (Fig. 2A). Unadjusted survival of
children in the NY cohort was signiﬁcantly more favorable
than survival of patients in the other 2 cohorts (Fig. 2B).
Table 1 Patient Characteristics and Clinical and Hemodynamic Parameters at Diagnosis Stratiﬁed by Center Cohort
All Patients New York Cohort Denver Cohort Dutch Cohort
p ValueN Value n Value n Value n Value
Age at diagnosis, yrs 275 6.4 (2.5–11.8) 135 7.2 (2.6–12.1) 93 5.0 (2.5–9.7) 47 7.9 (2.5–13.7) 0.283
Age at ﬁrst symptoms, yrs 225 5.0 (1.1–10.1) 124 4.5 (0.6–9.7) 55 5.1 (2.5–10.1) 46 6.1 (0.7–11.4) 0.260
Time from ﬁrst symptoms
to diagnosis, months
225 7.6 (2.2–22.9) 124 11.7 (4.2–29.7) 55 3.4 (0.7–12.2) 46 4.1 (2.0–15.1) <0.001*y
Incident patients 275 244 (89) 135 114 (84) 93 87 (94) 47 43 (92) 0.087
Female 275 162 (59) 135 81 (60) 93 55 (59) 47 26 (55) 0.869
Ethnicity 275 135 93 47 0.004y
Caucasian 187 (68) 78 (58) 68 (73) 41 (87)
Black 13 (5) 8 (6) 3 (3) 2 (4)
Asian 23 (8) 17 (13) 4 (4) 2 (4)
Hispanic 33 (12) 17 (13) 14 (15) 2 (4)
Other or unknown 19 (7) 15 (11) 4 (4) 0
Down syndrome 275 35 (13) 135 12 (9) 93 18 (19) 47 5 (11) 0.059
Diagnosis 275 135 93 47 0.023
IPAH/HPAH 144 (52) 76 (56) 40 (43) 28 (60)
PAH-CHD 114 (42) 54 (40) 47 (51) 13 (28)
No shunt 6 (5) 1 (2) 5 (11) 0 0.011z
Pre-tricuspid shunt 13 (11) 4 (7) 8 (17) 1 (8)
Post-tricuspid shunt 54 (47) 30 (56) 13 (28) 11 (85)
Repaired pre-tricuspid shunt 6 (5) 2 (4) 4 (9) 0
Repaired post-tricuspid shunt 35 (31) 17 (32) 17 (36) 1 (8)
Eisenmenger syndromex 14 (12) 7 (13) 3 (6) 4 (31) 0.067
APAH-non-CHD 17 (6) 5 (4) 6 (7) 6 (13)
Symptoms at diagnosis 215 109 59 47
Dyspnea in rest 27 (13) 13 (12) 0 14 (30) <0.001*yz
Dyspnea on exertion 124 (58) 63 (58) 25 (42) 36 (77) 0.002z
Chest discomfort 29 (13) 22 (20) 5 (9) 2 (4) 0.012y
Fatigue 52 (24) 26 (24) 19 (32) 7 (15) 0.117
Syncope 36 (17) 23 (21) 4 (7) 9 (19) 0.053
WHO functional class 236 123 67 46 0.011yz
I 14 (6) 13 (11) 0 1 (2)
II 107 (45) 56 (46) 40 (60) 11 (24)
III 78 (33) 33 (27) 18 (27) 27 (59)
IV 37 (16) 21 (17) 9 (13) 7 (15)
Height, cm 193 119.3  34.1 88 123.4  32.4 63 112.3  34.1 42 121.4  36.7 0.131
Weight, kg 198 29.0  21.1 90 31.3  22.3 63 25.5  19.0 45 29.2  21.1 0.242
BMI, kg/m2 192 17.8  5.0 87 18.5  5.6 63 17.2  4.3 42 17.3  4.4 0.262
Z-score height 193 0.87  1.5 88 0.78  1.27 63 1.11  1.68 42 0.72  1.61 0.295
Z-score BMI 190 0.12  1.6 87 0.07  1.63 62 0.22  1.45 41 0.36  1.58 0.299
TcSO2, % 166 94  7 70 95  4 59 92  8 37 92  8 0.020
6MWD, m 72 428  100 34 471  71 20 444  103 18 329  75 <0.001yz
Log value of NT-proBNP 41 2.85  0.77 d 15 2.85  0.82 26 2.85  0.76 0.991
Log value of BNP 51 1.91  0.63 20 2.03  0.46 26 1.96  0.67 5 1.33  0.86 0.079
Systolic blood pressure, mm Hg 190 96  16 91 99  12 66 87  17 33 104  16 <0.001*z
Diastolic blood pressure, mm Hg 181 58  12 82 63  10 66 51  12 33 62  12 <0.001*z
mPAP, mm Hg 275 55  18 135 57  19 93 52  19 47 53  16 0.094
mSAP, mm Hg 273 66  14 134 68  14 92 66  14 47 59  13 <0.001yz
mRAP, mm Hg 269 6  3 131 6  3 92 7  3 46 7  4 0.241
mPCWP, mm Hg 275 9  3 135 8  3 93 9  3 47 9  3 0.666
Qsi, l/min/m2 270 3.60  1.73 131 3.73  1.91 93 3.67  1.34 46 3.10  1.85 0.089
Qpi, l/min/m2 275 3.65  1.74 135 3.86  1.98 93 3.77  1.53 47 2.78  1.03 0.001yz
PVRi, WU$m2 275 15.81  10.79 135 15.93  10.62 93 14.01  10.20 47 19.04  11.83 0.032z
SVRi, WU$m2 252 19.78  10.69 117 20.96  11.80 90 18.27  10.01 45 19.75  8.62 0.200
mPAP/mSAP 273 0.86  0.30 134 0.87  0.30 92 0.81  0.29 47 0.92  0.30 0.095
PVR/SVR 252 0.87  0.78 117 0.82  0.54 90 0.79  0.46 45 1.16  1.47 0.021yz
Continued on the next page
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Table 1 Continued
All Patients New York Cohort Denver Cohort Dutch Cohort
p ValueN Value n Value n Value n Value
Qp/Qs 270 1.05  0.31 131 1.08  0.35 93 1.04  0.24 46 1.00  0.34 0.336
Acute vasodilator response
Sitbon criteria 217 29 (13) 98 14 (14) 79 12 (15) 40 3 (8) 0.475
Barst criteria 203 37 (18) 88 12 (14) 75 18 (24) 40 7 (18) 0.230
REVEAL childhood criteria 203 50 (25) 88 17 (19) 75 23 (31) 40 10 (25) 0.245
Values are mean  SD, median (interquartile range), or n (%). *Post-hoc test with Bonferroni correction shows a p value <0.05 between the Denver and NY cohorts. yPost-hoc test with Bonferroni correction
shows a p value <0.05 between the Dutch and NY cohorts. zPost-hoc test with Bonferroni correction shows a p value <0.05 between the Dutch and Denver cohorts. xOf all PAH-CHD patients, separate from
shunt types.
6MWD ¼ 6-min walk distance; APAH-non-CHD ¼ associated pulmonary arterial hypertension non-congenital heart disease; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; IPAH/HPAH ¼
idiopathic/hereditary PAH; mPAP ¼ mean pulmonary arterial pressure; mPAP/mSAP ¼ pulmonary-to-systemic arterial pressure ratio; mPCWP ¼ mean pulmonary capillary wedge pressure; mRAP ¼ mean
right atrial pressure; mSAP ¼ mean systemic arterial pressure; NT-proBNP ¼ N-terminal pro brain natriuretic peptide; PAH-CHD ¼ PAH associated with congenital heart disease; PVRi ¼ pulmonary vascular
resistance index; PVR/SVR ¼ pulmonary-to-systemic vascular resistance ratio; Qpi ¼ pulmonary blood ﬂow index; Qp/Qs ¼ pulmonary-to-systemic blood ﬂow ratio; Qsi ¼ systemic blood ﬂow index; REVEAL ¼
Registry to Evaluate Early and Long-Term PAH Disease Management; SVRi ¼ systemic vascular resistance index; TcSO2 ¼ transcutaneous oxygen saturation; WU ¼ Woods units.
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2163Within the Dutch cohort, 33% of the deceased patients died
within 3 months after diagnosis versus 6% and 0% of the
deceased Denver and NY patients, respectively. Exclusion of
these patients did diminish but not completely abolish the
survival differences among the center cohorts (Fig. 3A).
Thirty-three NY patients (24%), 6 Denver patients (7%),
and 2 Dutch patients (4%) were considered lost to follow-up
according to the study methodology (p < 0.001). In theory,
such patients could favorably bias survival estimates because
their potential death during the study period would not
be taken into account. To illustrate the maximal effect,
we estimated survival rates, hypothesizing that all such
patients had died, regardless of any knowledge of these
patients’ health status after the end of the study period. In
this worst-case scenario, no survival difference between the
center cohorts was observed (Fig. 3B).
Acute responders according to the Sitbon criteria had
better survival than those who did not meet the Sitbon
criteria (p ¼ 0.029). The Barst criteria and the REVEAL for
childhood-onset PAH criteria did not differentiate between
patients with better and worse survival in this population.
Univariate Cox regression analysis (Table 3) showed that
compared to children with IPAH/HPAH, those with PAH-Table 2 Treatment Strategy Stratiﬁed by Center
Treatment Strategy
All patients
(N ¼ 272)
New York C
(n ¼ 135
No speciﬁc PAH therapy 13 (5) 3 (2)
CCB monotherapy 24 (9) 11 (8)
PAH-targeted monotherapy 96 (35) 44 (33
Without IV/SC prostanoids 76 (28) 31 (23
With IV/SC prostanoids 20 (7) 13 (10
PAH-targeted dual therapy 92 (34) 48 (36
Without IV/SC prostanoids 51 (19) 28 (21
With IV/SC prostanoids 41 (15) 20 (15
PAH-targeted triple therapy 47 (17) 29 (21
Without IV/SC prostanoids 14 (5) 10 (7)
With IV/SC prostanoids 33 (12) 19 (14
Values are n (%).
CCB ¼ calcium channel blocker; IV ¼ intravenous; PAH ¼ pulmonary arteCHD had better transplantation-free survival, whereas those
with APAH-non-CHD had worse survival. Furthermore,
younger age at ﬁrst symptoms, lower WHO functional class,
lower systemic blood pressure, lower plasma N-terminal pro
brainnatriuretic peptide (NT-proBNP), lowermean right atrial
pressure, higher systemic blood ﬂow index, lower PVRi, and
lower mPAP/mSAPwere associated with better outcome. Sex,
ethnicity, Down syndrome, age at diagnosis, syncope, 6-min
walk distance, z-scores for height and body mass index, plasma
brain natriuretic peptide (BNP), and mean pulmonary arterial
pressure were not associated with transplantation-free survival.
NT-proBNP and systolic and diastolic blood pressure
were excluded from multivariate analysis because of >20%
missing cases. Multivariate backward stepwise Cox regres-
sion analysis with the remaining variables that emerged from
univariate analysis showed that diagnosis, WHO functional
class, PVRi, mPAP/mSAP, and treatment strategy were
the strongest independent predictors of transplantation-free
survival (Table 4). To eliminate a potential effect of PAH-
CHD patients with an open shunt for the value of these
predictors, we repeated these analyses after exclusion of these
67 patients, which did not change these ﬁndings. Also, the
ﬁndings did not change when accounting for referral center.Cohort
ohort
)
Denver Cohort
(n ¼ 92)
Dutch Cohort
(n ¼ 45) p Value
5 (5) 5 (11) 0.088
10 (11) 3 (7)
) 34 (37) 18 (40)
) 32 (35) 13 (29)
) 2 (2) 5 (11)
) 28 (30) 16 (36)
) 13 (14) 10 (22)
) 15 (16) 6 (13)
) 15 (16) 3 (7)
3 (3) 1 (2)
) 12 (13) 2 (4)
rial hypertension; SC ¼ subcutaneous.
Figure 1
Real-Time Therapy Per Center Cohort During a
7-Year Follow-Up Period
Real-time cumulative percentages of all patients per therapy group were plotted
for the NY cohort (A), the Denver cohort (B), and the Dutch cohort (C). This plot
shows the actual percent of patients in a speciﬁc therapy group, patients who
died, and patients who were censored per follow-up time point. For example,
40% of the NY cohort at diagnosis (time point 0) did not receive any speciﬁc
PAH therapy; after 1 year, 10% of this cohort received no speciﬁc PAH therapy;
and after 5 years, 2% received no speciﬁc PAH therapy. The legend key is shown
in the same descending order as in the ﬁgure. PAH ¼ pulmonary arterial
hypertension.
Table 3
Patient, Baseline Clinical, and Hemodynamic
Characteristics Associated With Survival
Univariate Cox Regression Analysis
Hazard Ratio (95% CI) p Value
Cohort
New York 1.00
Denver 2.356 (1.153–4.814) 0.019
Dutch 4.612 (2.215–9.602) <0.001
Diagnosis
IPAH/HPAH 1.00
PAH-CHD 0.470 (0.228–0.966) 0.040
APAH-non-CHD 3.986 (1.798–8.836) 0.001
Age at ﬁrst symptoms 1.080 (1.012–1.153) 0.020
WHO functional class III–IV versus I–II 2.231 (1.087–4.579) 0.029
Systolic blood pressure 1.030 (1.005–1.057) 0.020
Diastolic blood pressure 1.039 (1.005–1.075) 0.026
Log value of NT-proBNP 4.042 (1.173–13.926) 0.027
mRAP 1.107 (1.035–1.183) 0.003
Systemic blood ﬂow index 0.734 (0.576–0.935) 0.012
PVRi 1.034 (1.011–1.057) 0.003
mPAP/mSAP* 1.133 (1.033–1.243) 0.008
Treatment strategy
PAH-targeted monotherapy 1.00
No speciﬁc PAH therapy 2.057 (0.828–5.108) 0.120
CCB monotherapy 0.121 (0.016–0.904) 0.040
PAH-targeted dual therapy 0.421 (0.203–0.874) 0.020
PAH-targeted triple therapy 0.401 (0.175–0.923) 0.032
*Hazard ratio per 0.1 change of mPAP/mSAP.
APAH-non-CHD ¼ associated pulmonary arterial hypertension non-congenital heart disease;
CCB ¼ calcium channel blocker; CI ¼ conﬁdence interval; IPAH/HPAH ¼ idiopathic/hereditary PAH;
mPAP/mSAP ¼ pulmonary-to-systemic arterial pressure ratio; mRAP ¼ mean right atrial pressure;
NT-proBNP ¼ N-terminal pro brain natriuretic peptide; PAH-CHD ¼ PAH associated with congenital
heart disease; PVRi ¼ pulmonary vascular resistance index; WHO ¼ World Health Organization.
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2164In the total population, during the study period, 5% of
patients did not receive any speciﬁc PAH therapy, 9% of
patients continued CCB monotherapy, 35% of patients were
treated with PAH-targeted monotherapy, and 34% and 17%
were treated with dual and triple therapy, respectively
(Table 2). Figure 4 shows survival rates stratiﬁed by treat-
ment strategy. Patients’ disease severity at diagnosis (deﬁned
by the identiﬁed predictors of survival) is shown in Tables 5
and 6. Patients receiving CCB monotherapy had signiﬁ-
cantly better hemodynamics than patients taking PAH-
targeted therapy. Patients treated with dual and
triple therapy during the study period had a diagnosis of
PAH-CHD less frequently, higher mPAP/mSAP, and
tended to have higher WHO functional class and PVRi at
diagnosis than patients who were treated with monotherapy.
Patients who received IV/SC prostanoids had signiﬁcantly
higher WHO functional class and worse hemodynamics
than patients who did not receive IV/SC prostanoids. Cox
regression analysis indicated that dual and triple therapy
treatments during the study period were associated with
better survival than treatment with monotherapy. Although
the non-use of PAH drugs was associated with worse
survival compared to monotherapy in multivariate analysis,
Figure 2 Survival of All Included Pediatric PAH Patients and Stratiﬁed by Center Cohort
Kaplan-Meier curves showing the survival (A) for all included pediatric PAH patients: 1-, 3-, 5-, and 7-year transplantation-free survival rates were 96%, 89%, 81%, and 79%,
respectively. (B) For all patients stratiﬁed by center cohort: 1-, 3-, 5-, and 7-year survival rates were 100%, 96%, 90%, and 90% for NY; 95%, 87%, 78%, and 72% for Denver; and
84%, 71%, 62%, and 62% for NL, respectively (p < 0.001). Signiﬁcant survival differences existed between all 3 center cohorts. PAH ¼ pulmonary arterial hypertension.
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2165we consider the “no-therapy group” not to be a meaningful
control group for patients taking therapy, due to the com-
position of this group, including both patients with low
WHO functional classes doing well without therapy and
patients who died shortly after diagnosis.
In secondary sensitivity analyses, in which the robustness
of the multivariate models was assessed in 3 different data-
sets, the variables mPAP/mSAP (78% to 89%), diagnosis
(63% to 97%), and treatment strategy (50% to 95%) were
selected in more than 50% of the models, whereas WHO
functional class and PVRi were not.Figure 3 Survival of Pediatric PAH Patients Adjusted for Early Death
Kaplan-Meier curves show survival stratiﬁed by center cohort (A) after exclusion of all patie
the NY cohort and the other 2 cohorts persist. (B) Assuming all patients lost to follow-up
cohorts.Discussion
By direct comparison of contemporary patient cohorts from
3 major pediatric PAH referral centers, using standardized
inclusion criteria, differences in unadjusted, transplantation-
free survival rates were observed. However, adjustment for
clinical and hemodynamic patient characteristics, which
were identiﬁed as predictors of survival in the total cohort,
resolved the survival differences among the center cohorts.
Independent of these patient-related predictors, treatment
with combination therapy with PAH-targeted drugsand Patients Lost to Follow-Up
nts who died within 3 months after diagnosis. Signiﬁcant survival differences between
died. Now, no signiﬁcant survival difference could be observed between the center
Table 4
Multivariate Backward Stepwise Cox Regression
Analysis of Parameters Associated With Survival
(N ¼ 196)
Backward Stepwise Cox
Regression Analysis
Hazard Ratio (95% CI) p Value
Diagnosis
IPAH/HPAH 1.00
PAH-CHD 0.103 (0.027–0.396) 0.001
APAH-non-CHD 15.974 (4.402–57.960) <0.001
WHO functional class III–IV versus I–II 3.251 (1.316–8.028) 0.011
PVRi 1.053 (1.017–1.090) 0.003
mPAP/mSAP* 1.282 (1.104–1.489) 0.001
Treatment strategy
PAH-targeted monotherapy 1.00
No speciﬁc PAH therapyy 19.311 (3.682–101.274) <0.001
CCB monotherapy 0.385 (0.047–3.191) 0.377
PAH-targeted dual therapy 0.156 (0.057–0.422) <0.001
PAH-targeted triple therapy 0.094 (0.029–0.302) <0.001
*Hazard ratio per 0.1 change of mPAP/mSAP. yThis “non-treated” group consisted of patients who
were clinically very well without therapy or who died rapidly after diagnosis before therapy could be
started. In this statistical analysis, the hazard ratio seems determined predominantly by the rapidly
dying patients, not doing justice to the patients doing very well without treatment. Therefore this is
regarded as not a meaningful hazard ratio.
APAH-non-CHD ¼ associated pulmonary arterial hypertension non-congenital heart disease;
CCB ¼ calcium channel blocker; CI ¼ conﬁdence interval; IPAH/HPAH ¼ idiopathic/hereditary
PAH; mPAP/mSAP ¼ pulmonary-to-systemic arterial pressure ratio; PAH-CHD ¼ PAH associated
with congenital heart disease; PVRi ¼ pulmonary vascular resistance index; WHO ¼World Health
Organization.
Figure 4
Survival of Pediatric PAH Patients Stratiﬁed by
Treatment Strategy
Kaplan-Meier curves show survival stratiﬁed by treatment strategy (A) for all
patients; (B) for patients who did not receive intravenous/subcutaneous
prostanoids; and (C) for patients who did receive intravenous/subcutaneous
prostanoids. PAH ¼ pulmonary arterial hypertension.
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2166during the study period was associated with better survival
than treatment with monotherapy with a PAH-targeted
drug.
Parameters associated with survival. Children with
APAH-non-CHD had signiﬁcantly worse survival, whereas
those with PAH-CHD showed favorable survival compared
to IPAH/HPAH patients. This is congruent with several
previous reports, although discrepant data also have been
reported that show similar survival rates for pediatric
PAH-CHD and IPAH/HPAH patients (6,7,9,18). These
reported discrepancies may be due to the heterogeneity of the
heart defects that underlie PAH-CHD (e.g., closed versus
open shunts, simple versus complex defects) for which sur-
vival rates may differ (18). Further studies of this issue are
needed.
WHO functional class is a non-invasive but subjective
assessment of clinical condition that is widely used to predict
outcome and guide therapy in adult PAH (1,19). Its
applicability in pediatric PAH has been debated as WHO
functional class may be difﬁcult to assess in infants and
young children. However, various major referral centers for
pediatric PAH have independently shown WHO functional
class to be an important predictor of outcome, which was
conﬁrmed in the primary analysis in this study (7–9,20).
Secondary sensitivity analyses in the current study could not
conﬁrm the robustness of WHO functional class as an in-
dependent predictor. This indicates that further studies, in
addition to the current study, are needed to conﬁrm the
robustness of WHO functional class as independent pre-
dictor of outcome in pediatric PAH. A functional
Table 5 Predictors of Outcome Stratiﬁed by Treatment Strategy
Predictor
CCB Monotherapy
PAH-Targeted Therapy
p Value* p Valuey
Monotherapy Dual Therapy Triple Therapy
N Value N Value N Value N Value
Diagnosis 24 96 92 47 <0.001 0.164
IPAH/HPAH 17 (71) 31 (32) 52 (57) 37 (79)
PAH-CHD 7 (29) 56 (58) 33 (36) 9 (19)
APAH-non-CHD 0 9 (9) 7 (8) 1 (2)
WHO functional class 21 74 89 40 0.078 0.271
I–II 13 (62) 44 (60) 40 (45) 16 (40)
III–IV 8 (38) 30 (41) 49 (55) 24 (60)
PVRi 24 8.73  5.63 96 15.09  10.99 92 16.84  11.08 47 19.51  9.27 0.068 <0.001
mPAP/mSAP 24 0.58  0.21 94 0.80  0.26 92 0.94  0.27 47 0.95  0.32 0.001 <0.001
Values are mean  SD or n (%). *p Values for PAH-targeted mono- versus dual versus triple therapy. yp Values for CCB monotherapy versus PAH-targeted therapy.
APAH-non-CHD ¼ associated pulmonary arterial hypertension non-congenital heart disease; CCB ¼ calcium channel blocker; IPAH/HPAH ¼ idiopathic/hereditary PAH; mPAP/mSAP ¼ pulmonary-to-
systemic arterial pressure ratio; PAH-CHD ¼ PAH associated with congenital heart disease; PVRi ¼ pulmonary vascular resistance index; WHO ¼ World Health Organization.
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2167classiﬁcation system customized for young children has been
proposed but has yet to be validated (21).
The hemodynamic parameters independently associated
with survival in this study have previously been identiﬁed as
predictors of outcome in other, mostly single-center studies
(7,10,22). Hemodynamic parameters have the advantages
of objectivity and obtainability at any age. However, an
important disadvantage is the need for a cardiac catheter-
ization procedure, which often requires anesthesia or
sedation in infants and young children with associated
risks. In contrast to the Barst and REVEAL for childhood-
onset PAH criteria, acute responders according to the
Sitbon criteria had better survival than non-responders
in this study, conﬁrming previous reports (22). Therefore,
the Sitbon criteria seem to be applicable also in children
and may better predict long-term survival in pediatric
PAH.
In the current study, the natriuretic peptides BNP and
NT-proBNP were available at diagnosis only for a small
number of patients. We could not demonstrate an associ-
ation between BNP and survival. However, despite low
numbers, NT-proBNP was associated with survival,Table 6 Predictors of Outcome Stratiﬁed by Use of IV/SC Prostanoi
Predictor
No IV/SC Prostanoids Used
Monotherapy
(N ¼ 76)
Dual
(N ¼ 51)
Triple
(N ¼ 14) p Va
Diagnosis <0.
IPAH/HPAH 18 (24) 20 (39) 12 (86)
PAH-CHD 52 (68) 27 (53) 2 (14)
APAH-non-CHD 6 (8) 4 (8) 0
WHO functional class (N ¼ 56) (N ¼ 50) (N ¼ 14) 0.
I–II 40 (71) 32 (64) 6 (43)
III–IV 16 (29) 18 (36) 8 (57)
PVRi 13.63  10.66 15.38  10.65 17.09  7.79 0.
mPAP/mSAP 0.75  0.24 0.89  0.23 0.94  0.40 0.
Values are mean  SD or n (%). *p Values for PAH-targeted monotherapy versus dual versus triple therapy
prostanoids used versus IV/SC prostanoids used.
Abbreviations as in Table 5.conﬁrming previous reports (9,23,24). Due to these low
numbers, NT-proBNP could not be included in multi-
variate analysis, limiting its evaluation as an independent
predictor. However, on the basis of the currently available
data, the authors feel that NT-proBNP should be part
of the standardized follow-up for children with PAH
and be included in future studies in order to adequately
assess its value as an independent predictor of survival in
pediatric PAH.
Other parameters, which have been previously reported to
be associated with survival in pediatric PAH, such as age at
diagnosis and z-score for height, were not associated with
survival in the current study (10,20).
Survival differences among the center cohorts. There
were relatively more IPAH/HPAH and APAH-non-CHD
patients in the Dutch cohort than in the U.S. cohorts, which
attributed to the observed survival differences.
Based on WHO functional class and hemodynamics,
children in the Dutch cohort appeared to have more severe
disease than children in the U.S. cohorts. Differences in the
organization of care and referral patterns, in traveling dis-
tances and in accessibility to referral centers, may be factorsds and PAH-Targeted Mono-, Dual, and Triple Therapy
IV/SC Prostanoids Used
p Value* p Valueylue*
Monotherapy
(N ¼ 20)
Dual
(N ¼ 41)
Triple
(N ¼ 33)
001 0.529 <0.001
13 (65) 32 (78) 25 (76)
4 (20) 6 (15) 7 (21)
3 (15) 3 (7) 1 (3)
134 (N ¼ 18) (N ¼ 39) (N ¼ 26) 0.251 <0.001
4 (22) 8 (21) 10 (39)
14 (79) 31 (80) 16 (62)
421 20.64  10.68 18.66  11.47 20.54  9.75 0.692 <0.001
003 0.98  0.23 0.99  0.30 0.96  0.30 0.843 <0.001
within the no-IV/SC prostanoids used and the IV/SC prostanoids used groups. yp Values for no IV/SC
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representation of the most severely ill patients. Such patients
may not always reach the referral centers in the United
States. Such factors could explain the observed difference in
disease severity between the center cohorts.
Also, the proportion of patients lost to follow-up, which
differed among the center cohorts, may attribute to the
observed survival differences. In a hypothetical worst-case
scenario, where all patients lost to follow-up are assumed
dead (obviously representing an over-estimate of the number
of deaths), a survival difference between the center cohorts
could not be demonstrated.
Treatment patterns, as deﬁned for this study (CCB
monotherapy or PAH-targeted monotherapy, or dual or
triple therapy), did not differ among the center cohorts and,
thus, did not contribute to the survival differences between
the center cohorts.
Treatment. Our ﬁndings conﬁrm that, as in adult PAH, in
pediatric PAH a small select subgroup of patients (with
favorable hemodynamics) has a favorable, long-term survival
with CCB monotherapy without the need for additional
PAH-targeted therapy (25).
In this study, treatments with PAH-targeted dual and
triple therapy during the study period were associated with
better survival than treatment with PAH-targeted mono-
therapy, whether or not treatment strategy included IV/SC
prostanoids. Differences in disease severity at diagnosis could
not explain the observed survival differences among patients
taking monotherapy or dual and triple therapy. Patients who
received IV/SC prostanoid therapy had more severe disease
at diagnosis. These data also illustrate that IV/SC prosta-
noids as monotherapy may not sufﬁce in children with severe
disease and is associated with poor outcome. Therefore, this
study provides additional support for the notion of a more
aggressive treatment approach in pediatric PAH, with the
use of combination therapy. Given the relatively large pro-
portion of patients receiving monotherapy found in all
3 center cohorts, there may be room for improvement in this
respect. Whether an initial or an add-on treatment strategy
would be most beneﬁcial to improve outcome in pediatric
PAH patients should be further evaluated.
A goal-oriented treatment strategy aiming at predeﬁned
improvement of the clinical condition instead of reacting to
deterioration of the patient’s clinical condition and leading to
intensiﬁcation of treatment has been suggested to improve
outcome in adult PAH (26,27). Such a strategy is likely to be
beneﬁcial also in pediatric PAH.However, in contrast to adult
PAH, treatment goals to guide goal-oriented treatment are
neither well deﬁned nor validated in pediatric PAH (12). The
parameters identiﬁed to predict survival in this study may
qualify for such treatment goals in the future. However,
further research is essential to establish and validate treatment
goals and to determine the effects of a goal-oriented treatment
strategy on survival in this vulnerable patient population.
Study limitations. Retrospective studies come with certain
limitations. However, the 3 center cohorts that were broughttogether come from 3 PAH-dedicated centers with stan-
dardized diagnostic and treatment protocols, minimizing
these limitations. Multivariate analysis was limited by
missing values within speciﬁc parameters that may be caused
by either different diagnostic and follow-up strategies among
centers or by the inherent impossibility of obtaining certain
data in certain age or patient groups. In the analyses
regarding treatment strategy, individual variations in doses
and time relationships were not taken into account, pre-
cluding deﬁnitive conclusions on a causal relationship
between treatment strategy and outcome. To address the risk
of overﬁtting in this relatively small study, we performed
secondary sensitivity analyses, in which the variables diag-
nosis, mPAP/mSAP, and treatment strategy were conﬁrmed
to be independent predictors of outcome, whereas WHO
functional class and PVRi could not be conﬁrmed in these
secondary analyses, indicating that their robustness as in-
dependent predictors of outcome should be further studied.
Diagnostic cardiac catheterizations were performed under
both general anesthesia and conscious sedation. A potential
effect of the mode of anesthesia on hemodynamics was not
investigated in this study. Furthermore, the moderately high
altitude of Denver was not taken into account in this study
and may have negatively biased the outcome of the Denver
cohort. Bringing together the complete consecutive patient
cohorts of 3 major referral centers for pediatric PAH pro-
vided a unique opportunity to validate clinical patient
characteristics that appeared to be responsible for observed
survival differences and to ﬁnd clues to optimize and guide
therapy.Conclusions
Unadjusted survival rates of pediatric PAH patients differed
among 3 major referral centers. This study identiﬁed diag-
nosis, WHO functional class, mPAP/mSAP, and PVRi as
independent predictors of outcome that could explain the
observed survival differences among the center cohorts.
Moreover, we found that treatment with PAH-targeted
combination therapy during the study period was indepen-
dently associated with improved transplantation-free sur-
vival. Secondary sensitivity analyses indicated that the
robustness of WHO functional class and PVRi as predictors
of outcome in pediatric PAH deserves further evaluation.
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